Esperion Therapeutics (NASDAQ:ESPR) Stock Crosses Above 50-Day Moving Average – What’s Next?

Esperion Therapeutics, Inc. (NASDAQ:ESPR) shares crossed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $2.59 and traded as high as $3.13. Esperion Therapeutics shares last traded at $3.12, with a volume of 6,795,157 shares.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. Citizens Jmp downgraded shares of Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, May 1st. Jefferies Financial Group downgraded shares of Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, May 1st. Wall Street Zen upgraded shares of Esperion Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, March 14th. Needham & Company LLC downgraded shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, May 4th. Finally, HC Wainwright downgraded shares of Esperion Therapeutics from a “buy” rating to a “neutral” rating and set a $3.16 target price for the company. in a report on Friday, May 1st. One analyst has rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $5.54.

Esperion Therapeutics Price Performance

The company’s fifty day moving average price is $2.59 and its 200 day moving average price is $3.11. The company has a market cap of $803.18 million, a PE ratio of -52.00, a P/E/G ratio of 2.54 and a beta of 0.91.

Esperion Therapeutics (NASDAQ:ESPR) last announced its earnings results on Friday, May 8th. The biopharmaceutical company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.08). The firm had revenue of $80.10 million during the quarter, compared to analysts’ expectations of $84.52 million. Esperion Therapeutics had a net margin of 0.12% and a negative return on equity of 0.14%. On average, analysts forecast that Esperion Therapeutics, Inc. will post 0.05 EPS for the current year.

Hedge Funds Weigh In On Esperion Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. grew its position in Esperion Therapeutics by 68.4% during the third quarter. JPMorgan Chase & Co. now owns 945,491 shares of the biopharmaceutical company’s stock valued at $2,506,000 after buying an additional 384,095 shares during the period. Royce & Associates LP bought a new position in Esperion Therapeutics during the third quarter valued at about $6,078,000. AIGH Capital Management LLC grew its position in Esperion Therapeutics by 33.3% during the fourth quarter. AIGH Capital Management LLC now owns 4,000,000 shares of the biopharmaceutical company’s stock valued at $14,800,000 after buying an additional 1,000,000 shares during the period. Integral Health Asset Management LLC bought a new position in Esperion Therapeutics during the third quarter valued at about $3,975,000. Finally, Vanguard Group Inc. grew its position in Esperion Therapeutics by 23.6% during the fourth quarter. Vanguard Group Inc. now owns 14,945,454 shares of the biopharmaceutical company’s stock valued at $55,298,000 after buying an additional 2,853,005 shares during the period. Institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.